Myeloproliferative Neoplasms News

The FDA granted orphan drug designation to SY-1425 for the treatment of acute myeloid leukemia, according to the drug’s manufacturer.

Fox Chase Cancer Center announced several appointments.

HemOnc Today presents 10 advances in the treatment of leukemia, lymphoma, myeloma and myeloproliferative neoplasms that may be relevant to your practice and help improve patient care.

Vorinostat appeared safe and effective combined with standard graft-versus-host disease prophylaxis for patients undergoing matched unrelated donor hematopoietic stem cell transplantation with myeloablative conditioning, according to a single-center, prospective phase 2 study published in Blood.

Older patients with cancer often reported having better physical function, mental health and social support than their caregivers’ assessments, according to study results published in The Oncologist.

One-third of insured patients with cancer had out-of-pocket costs that exceeded their expectations, according to study results.

The FDA approved ibrutinib for the treatment of adults with chronic graft-versus-host disease who failed prior systemic therapy.

Patients with advanced cancer who arrived at the ED with delirium had increased rates of hospitalization and ICU admissions, as well as shorter survival rates, according to a study published in The Oncologist.

Patients with advanced cancer had significantly lower survival rates following in-hospital cardiac arrest than those without advanced cancer, according to a retrospective study published in Journal of Oncology Practice.

Four leading national cancer organizations have united in their mission to reduce the number of health disparities in the United States and to ensure all patients, regardless of social demographics and socioeconomic status, benefit from cancer research, according to a joint position statement published in Journal of Clinical Oncology.